These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 18398105

  • 1. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
    Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):563-71. PubMed ID: 18398105
    [Abstract] [Full Text] [Related]

  • 2. Re: Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
    Wood C, Cline M.
    J Natl Cancer Inst; 2008 Sep 17; 100(18):1335; author reply 1335-6. PubMed ID: 18780867
    [No Abstract] [Full Text] [Related]

  • 3. Menstrual and reproductive history, postmenopausal hormone use, and risk of benign proliferative epithelial disorders of the breast: a cohort study.
    Cui Y, Page DL, Lane DS, Rohan TE.
    Breast Cancer Res Treat; 2009 Mar 17; 114(1):113-20. PubMed ID: 18360772
    [Abstract] [Full Text] [Related]

  • 4. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS, Women's Health Initiative Mammogram Density Study Investigators.
    J Natl Cancer Inst; 2005 Sep 21; 97(18):1366-76. PubMed ID: 16174858
    [Abstract] [Full Text] [Related]

  • 5. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, David Curb J, Hendrix SL, Allan Hubbell F, Khandekar J, Lane DS, Lasser N, Lopez AM, Potter J, Ritenbaugh C.
    Maturitas; 2006 Sep 20; 55(2):103-15. PubMed ID: 16815651
    [Abstract] [Full Text] [Related]

  • 6. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H, Stevenson J.
    Gynecol Endocrinol; 2006 Jun 20; 22(6):303-17. PubMed ID: 16785155
    [Abstract] [Full Text] [Related]

  • 7. Estrogen plus progestin and risk of benign proliferative breast disease.
    Rohan TE, Negassa A, Chlebowski RT, Lasser NL, McTiernan A, Schenken RS, Ginsberg M, Wassertheil-Smoller S, Page DL.
    Cancer Epidemiol Biomarkers Prev; 2008 Sep 20; 17(9):2337-43. PubMed ID: 18725513
    [Abstract] [Full Text] [Related]

  • 8. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative.
    Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J, WHI Investigators.
    Circulation; 2006 May 23; 113(20):2425-34. PubMed ID: 16702472
    [Abstract] [Full Text] [Related]

  • 9. Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative.
    Hsia J, Criqui MH, Herrington DM, Manson JE, Wu L, Heckbert SR, Allison M, McDermott MM, Robinson J, Masaki K, Women's Health Initiative Research Group.
    Am Heart J; 2006 Jul 23; 152(1):170-6. PubMed ID: 16824852
    [Abstract] [Full Text] [Related]

  • 10. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.
    Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R, Women's Health Initiative Investigators.
    Arch Intern Med; 2006 Feb 13; 166(3):357-65. PubMed ID: 16476878
    [Abstract] [Full Text] [Related]

  • 11. Venous thrombosis and conjugated equine estrogen in women without a uterus.
    Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR.
    Arch Intern Med; 2006 Apr 10; 166(7):772-80. PubMed ID: 16606815
    [Abstract] [Full Text] [Related]

  • 12. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial.
    Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG, Naughton MJ, Satterfield S, Bassford T, Women's Health Initiative Investigators.
    J Bone Miner Res; 2006 Jun 10; 21(6):817-28. PubMed ID: 16753012
    [Abstract] [Full Text] [Related]

  • 13. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
    Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J, HABITS Study Group.
    J Natl Cancer Inst; 2008 Apr 02; 100(7):475-82. PubMed ID: 18364505
    [Abstract] [Full Text] [Related]

  • 14. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women's Health Initiative Steering Committee.
    JAMA; 2004 Apr 14; 291(14):1701-12. PubMed ID: 15082697
    [Abstract] [Full Text] [Related]

  • 15. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
    Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH, Women's Health Initiative Memory Study.
    JAMA; 2004 Jun 23; 291(24):2947-58. PubMed ID: 15213206
    [Abstract] [Full Text] [Related]

  • 16. Cigarette smoking and risk of benign proliferative epithelial disorders of the breast in the Women's Health Initiative.
    Cui Y, Page DL, Chlebowski RT, Hsia J, Allan Hubbell F, Johnson KC, Rohan TE.
    Cancer Causes Control; 2007 May 23; 18(4):431-8. PubMed ID: 17323143
    [Abstract] [Full Text] [Related]

  • 17. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun 23; 13(71):106-9. PubMed ID: 15233153
    [Abstract] [Full Text] [Related]

  • 18. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types.
    Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA.
    Cancer Epidemiol Biomarkers Prev; 1997 May 23; 6(5):297-301. PubMed ID: 9149887
    [Abstract] [Full Text] [Related]

  • 19. Use of oral conjugated estrogen alone and risk of breast cancer.
    Zhang SM, Manson JE, Rexrode KM, Cook NR, Buring JE, Lee IM.
    Am J Epidemiol; 2007 Mar 01; 165(5):524-9. PubMed ID: 17132697
    [Abstract] [Full Text] [Related]

  • 20. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR, TREAT.
    Maturitas; 2005 Sep 16; 52(1):1-10. PubMed ID: 15963666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.